Affiliation:
1. Division of Cardiology Central Japan International Medical Center Gifu Japan
2. Division of Cardiology Nagoya Heart Center Nagoya Japan
3. Division of Cardiology Ogaki Municipal Hospital Ogaki Japan
4. Division of Vascular surgery Toyota Memorial Hospital Toyota Japan
5. Division of Cardiology Kyoto University Hospital Kyoto Japan
6. Division of Cardiology Shizuoka General Hospital Shizuoka Japan
7. Division of Molecular Pathology Shinshu University of Medicine Matsumoto Japan
Abstract
AbstractBackground and AimsPolymer‐coated drug‐eluting stents (Eluvia) have shown favorable clinical outcomes in real‐world registries. There are no reports on recurrent predictors after Eluvia placement based on intravascular ultrasound (IVUS) findings.MethodsWe analyzed clinical data from the ASIGARU PAD registry, a retrospective, multicenter, observational study that enrolled patients who underwent endovascular therapy for superficial femoral and proximal popliteal arteries lesions using Eluvia or drug‐coated balloon. The primary outcome was the identification of recurrent predictors, including IVUS parameters at 12 months. The rate of target lesion recurrence was also assessed.ResultsIVUS images were obtained in 54 of 65 cases. Seven recurrent cases (13.0%) were observed within 12 months. The random survival forest method presented eight predictive variables of recurrence: Clinical Frailty Scale (CFS), distal stent edge area, distal plaque burden, age, sex, distal external elastic membrane (EEM) area, minimum stent area (MSA), and distal lumen area. Furthermore, the partial dependence plot showed that frailty (CFS ≥ 6), smaller distal stent edge area, higher and lower distal plaque burden, older and younger age, female sex, smaller distal EEM area, smaller MSA, and smaller and larger distal lumen area predicted recurrence after Eluvia placement within 12 months.ConclusionCFS, distal stent edge area, distal plaque burden, age, sex, distal EEM area, MSA, and distal lumen area were significant recurrent predictors after Eluvia placement.